IF YOU can’t stomach undergoing surgery even if your problem is your bulging tummy, you might want to consider taking medication — of course, after you’ve checked with your doctor.
The main component of weight-control pill Lesofat is Orlistat that inhibits enzymes which break down dietary fat molecules.
"Orlistat is designed to prevent the body from breaking down and absorbing fat. Approximately 40% of the unabsorbed fat passes through the intestines and leaves the body through the feces," said Product Manager Paul Roland R. Cedeno.
A study conducted among obese patients done over a two-year period in the US shows that over 65% of patients on Orlistat lost more than 5% of their body weight on the first year of taking Orlistat three times a day.
Over 39% of the subjects who continued using Orlistat on the second year lost 10% of the body weight they registered when they enrolled in the research program.
Like all diet pills, Lesofat should be taken in tandem with a healthy diet and regular exercise for an effective weight-loss program.
If you’re more of a rice and bread eater, Xando is another option. Xando Block and Burn is described as a dietary tablet that helps people slim down and keep in shape by blocking carbohydrates, starch, sugar and fat.
It is clinically tested to help individuals lose weight three times faster. Taken with a healthy diet and light physical activity, Xando is supposed to help a person achieve and maintain his or her ideal weight.
The product was developed in Norway and contains natural ingredients such as kidney bean extract, chicory (chicorium intybus), and garcinia (garcinia cambogia fructus) that help block out calories from carbohydrates, starch, and sugar from food such as rice, noodles, pasta and bread.
It also contains a unique combination of phaseolamin, inulin and hydroxycitric acid (HCA) that reduces and burns unwanted body fat. Xando has no laxatives and caffeine making it ideal for people on the go.
Source: Business World
The Dark History of the Occult: Magic, Madness and Murder: Paul Roland[Aug 01, 2011]
ReplyDelete